I-Mab (NASDAQ: IMAB) is a biopharmaceutical company focused on the discovery, development, and commercialization of novel or highly differentiated biologics for immuno-oncology and autoimmune diseases. The company's pipeline includes several clinical-stage product candidates, such as TJ301, a potential treatment for cytokine storm associated with COVID-19 and CAR-T therapy; TJ210, an investigational drug for multiple myeloma; TJ107/Huobizai, a CD47 monoclonal antibody in phase 3 clinical trial for Hodgkin's lymphoma; and TJ101, a potential treatment for autoimmune diseases.
I-Mab has a proprietary discovery platform for antibody engineering and innovative protein technologies, which enables the company to rapidly develop and optimize product candidates. The company has several partnerships with leading biopharmaceutical companies, including AbbVie, ABL Bio, and Roche, to develop and commercialize its product candidates globally.
Headquartered in Shanghai, China, I-Mab was founded in 2016 and completed its initial public offering (IPO) on the Nasdaq Global Market in January 2020.
I-Mab (NASDAQ: IMAB) is a biopharmaceutical company focused on the discovery, development, and commercialization of novel or highly differentiated biologics for immuno-oncology and autoimmune diseases. The company's pipeline includes several clinical-stage product candidates, such as TJ301, a potential treatment for cytokine storm associated with COVID-19 and CAR-T therapy; TJ210, an investigational drug for multiple myeloma; TJ107/Huobizai, a CD47 monoclonal antibody in phase 3 clinical trial for Hodgkin's lymphoma; and TJ101, a potential treatment for autoimmune diseases.